Dyskeratosis congenita is a rare condition involving characteristic physical findings, as well as an increased risk for bone marrow failure and certain types of cancer. Early diagnosis is crucial to guide management, screening, and treatment for people who are affected.
Quick Reference
Test Code 8161
Turnaround Time (TAT) 2-4 weeks
Number of Genes 7

Ordering Options

We now offer single site analysis (SSA) at no additional cost to family members

following single gene or panel testing* of the first family member (proband) within 90 days of the original Ambry report date.

Order Now

*excludes Secondary Findings and SNP Array tests

Test Description

Our DCNext test includes next generation sequencing (NGS) and deletion/duplication analysis of DKC1, TINF2, TERC, NHP2, NOP10, WRAP53, and TERT. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, followed by polymerase chain reaction (PCR) and next generation sequencing (NGS). 

Additional Sanger sequencing is performed for any regions missing, or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.This test targets detection of DNA sequence mutations in all coding domains, and well into the 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis for TERC is performed via multiplex ligation probe amplification (MLPA, MRC Holland). Gross deletion/duplication analysis for all remaining genes is performed utilizing a targeted chromosomal microarray. 


  1. Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.
View Full Menu

Search Results

Start your search...